Efprezimod alfa

依瑞莫德α

Report date: 2026/05/18 20:02:07

Base Information

Drug NameEfprezimod alfa
Drug Alias NameCD24Fc-fusion proteinRecombinant CD24 IgG1 Fc fusion proteinrecombinant human CD24FcIghumanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domainSACCOVID +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-6 inhibitorsSialic acid-binding Ig-like lectin 10 antagonistsInterleukin-1 beta inhibitors +[4] 
TargetsSialic acid-binding Ig-like lectin 10Interleukin-6Tumor necrosis factor α +[4] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursGraft vs Host Disease +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOncoimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Ankang Immune Technology Co LtdOncoimmune IncMerck Sharp & Dohme Corp
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursDyslipidemias +[6] 

Other Information

ATC CodeN/A
Related LinksN/A